FDA-Approved Dual GIP/GLP-1 Real Physician Prescribed All 50 States

Get Zepbound® Prescribed Online — The Most Powerful Weight Loss Medication Available

Zepbound® (tirzepatide) is the first and only FDA-approved dual GIP/GLP-1 receptor agonist for weight loss — with clinical trials showing up to 22.5% body weight reduction. Real prescription, real results, licensed physician online.

Licensed US Physicians
FDA-Approved Medication
All 50 States
No Insurance Needed
Zepbound® Tirzepatide
Average Body Weight Lost in Clinical Trials
Zepbound® (tirzepatide) 22.5%
22.5%
Wegovy® (semaglutide) 15.3%
15.3%
Zepbound outperformed every other weight loss medication in head-to-head clinical trials — including 47% more weight loss than Wegovy®.
Get My Zepbound Prescription
About Zepbound®

Why Zepbound® Is the #1 Weight Loss Medication

Zepbound® works differently than every other weight loss drug on the market. Here's the science — and why it matters for your results.

A Dual-Action Mechanism Unlike Any Other

Zepbound® (tirzepatide) works differently from semaglutide — and that difference is significant. While Ozempic® and Wegovy® target only the GLP-1 receptor, Zepbound® activates two hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) AND GLP-1. This dual-action mechanism is why Zepbound® consistently produces more dramatic weight loss than GLP-1-only medications.

GLP-1 suppresses appetite and slows gastric emptying. GIP enhances the effect by improving fat metabolism and amplifying the satiety signal. Together, these two pathways create a synergistic effect that neither hormone achieves alone. This is not a subtle improvement — it translates to meaningfully greater weight loss for most patients.

What the Clinical Data Shows

The SURMOUNT-1 clinical trial, the largest weight-loss drug trial of its kind, showed that Zepbound® patients lost an average of up to 22.5% of their body weight over 72 weeks — results that surpassed every prior weight loss medication in history. For a 250-pound patient, that means up to 56 pounds lost on average.

More recently, the SURMOUNT-5 trial put Zepbound® head-to-head against Wegovy® — the first-ever direct comparison of these two medications. The result? Zepbound® patients lost 47% more weight than Wegovy® patients over the same 72-week period. Zepbound® won decisively. FDA-approved in November 2023 for chronic weight management in adults, it has rapidly become the most sought-after prescription weight loss treatment available.

Zepbound® At a Glance

Drug classDual GIP/GLP-1 Receptor Agonist
Active ingredientTirzepatide
Doses available2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
AdministrationWeekly subcutaneous injection
FDA ApprovalNovember 2023
Clinical trialSURMOUNT-1 — up to 22.5% avg weight loss
Head-to-headSURMOUNT-5 — 47% more loss than Wegovy®
ManufacturerEli Lilly and Company
Eligibility

Do You Qualify for Zepbound®?

Zepbound® is FDA-approved for adults who meet specific clinical criteria. Most patients who want it do qualify — here's what to know before your consultation.

BMI ≥ 30 (Obesity)

Adults with a body mass index at or above 30 qualify for Zepbound® without any additional conditions required.

BMI ≥ 27 + Weight-Related Condition

Adults with a BMI of 27–29.9 qualify if they have at least one weight-related condition: high blood pressure, type 2 diabetes, sleep apnea, or dyslipidemia.

Adults 18 and Older

Zepbound® is FDA-approved for adults aged 18 and up. It has not been approved for use in patients under 18 years of age.

Not Pregnant or Breastfeeding

Zepbound® is not recommended during pregnancy or breastfeeding. Patients should use contraception and discuss family planning with their physician.

No MTC or MEN2 History

Zepbound® should not be used by patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

No Tirzepatide Hypersensitivity

Patients with a known history of serious hypersensitivity reactions to tirzepatide or any ingredient in Zepbound® are not candidates for this medication.

Not sure if you qualify? Our physicians will review your complete medical history, current medications, and weight-loss goals during your free online consultation — at no cost and no commitment.

The Process

How to Get Zepbound® Prescribed Online

Three simple steps from your couch to your Zepbound® prescription. No waiting rooms, no referrals, no hassle.

Step 01

Complete Your Assessment

Fill out a confidential medical history form online in about 5 minutes. Our licensed physicians review your health profile, current medications, weight-loss history, BMI, and eligibility for Zepbound®. The entire process is HIPAA-secure and completely confidential. There is no charge for the initial assessment.

Step 02

Get Your Prescription

If you are a good candidate, a board-certified physician writes your Zepbound® prescription and sends it directly to your pharmacy. We coordinate with your insurance company and handle prior authorization paperwork on your behalf — so you can focus on your health, not the administrative headache.

Step 03

Medication Delivered

Your Zepbound® auto-injector pens ship directly to your preferred pharmacy or home address, depending on your coverage. Monthly check-ins with your Truventa physician keep you on track, and dose adjustments are made based on your response and tolerance. We're with you every step of the way.

Dosing Schedule

Zepbound® Dose Escalation Schedule

Zepbound® is always started at the lowest dose and gradually increased over time. This approach minimizes side effects and helps your body adapt to the medication.

Weeks 1–4: 2.5mg/week — Starter Dose

The starter dose is designed to build tolerance, not to produce maximum weight loss. Most patients experience mild appetite reduction at this stage. Any gastrointestinal side effects are typically at their mildest, and most patients tolerate this phase very well. Your physician will check in before escalating the dose.

Weeks 5–8: 5mg/week — First Therapeutic Dose

At 5mg, you enter the first true therapeutic dose. Appetite suppression becomes noticeably stronger, and most patients report meaningful reductions in hunger and food cravings — especially for high-calorie, high-sugar foods. Average weight loss by week 8 is typically 4–8 pounds depending on starting weight and lifestyle.

Weeks 9–12 (Optional): 7.5mg/week — Increased Efficacy

The 7.5mg dose increases weight loss efficacy further. Patients who tolerate 5mg well typically advance here. Weight loss accelerates during this phase, and many patients begin to notice visible changes in body composition. Monthly physician check-ins confirm you are on the right track.

Weeks 13–16 (Optional): 10mg/week — Approaching Maximum Effect

The 10mg dose represents a major step in Zepbound®'s efficacy profile. Many patients achieve their best results at this dose and find it to be their ideal maintenance level. Clinical data shows that most of Zepbound®'s weight loss benefit is captured by the time patients reach 10mg.

Weeks 17–20 (Optional): 12.5mg/week — Near-Maximum Dose

The 12.5mg dose is available for patients who are tolerating the medication well and wish to push toward maximum benefit. Your physician will evaluate whether escalating to this dose is appropriate based on your progress and overall health profile.

Week 21+ (Optional): 15mg/week — Maximum Dose

The 15mg weekly dose is the maximum approved dose of Zepbound® and was associated with the greatest weight loss in the SURMOUNT-1 clinical trial — an average of 22.5% body weight reduction over 72 weeks. Not every patient needs the maximum dose, and your physician will only recommend it if clinically appropriate.

Your Truventa physician will personalize your dose escalation. Many patients achieve their weight loss goals at 10mg without needing the maximum dose. Dose adjustments can always be slowed or paused if you experience side effects — there is no rush.

Comparison

Zepbound® vs Wegovy® — Head-to-Head

The first-ever direct clinical trial compared these two medications. The results were unambiguous.

Feature Zepbound® Wegovy®
Drug class Dual GIP/GLP-1 GLP-1 only
Active ingredient Tirzepatide Semaglutide
Average weight loss Up to 22.5% 15.3%
FDA approval for weight loss 2023 2021
Weekly injection
Head-to-head winner (SURMOUNT-5) Winner
Maximum dose 15mg/week 2.4mg/week
Receptor targets GIP + GLP-1 (2 receptors) GLP-1 (1 receptor)

In the first-ever head-to-head trial (SURMOUNT-5), Zepbound® patients lost 47% more weight than Wegovy® patients over 72 weeks. This was not a marginal difference — it was a landmark result that cemented Zepbound® as the most effective weight loss medication in clinical history.

Both Zepbound® and Wegovy® are available at Truventa Medical. Our physicians will recommend the best medication for your specific health profile, goals, and insurance coverage during your free consultation.

Start Free Consultation
Clinical Results

What Patients Achieve on Zepbound®

The SURMOUNT-1 trial enrolled 2,539 participants across 72 weeks. The results set new records for weight loss medicine.

SURMOUNT-1 Trial Results

Source: Jastreboff et al., NEJM 2022 | Tirzepatide 15mg dose, 72 weeks

Average body weight lost (15mg) Up to 22.5%
Participants who lost ≥5% body weight 91%
Participants who lost ≥10% body weight 83%
Participants who lost ≥15% body weight 57%
Participants who lost ≥20% body weight 36%
Average pounds lost (250 lb baseline) ~56 lbs

Real-World Health Benefits

Beyond the scale — what Zepbound® does for your overall health

Waist circumference: Significant reduction in abdominal fat, a key marker of metabolic and cardiovascular health
Blood sugar and HbA1c: Clinically meaningful improvements in glucose control, even in patients without diabetes
Blood pressure: Meaningful reductions in both systolic and diastolic blood pressure in trial participants
Sleep apnea: Significant improvement in sleep apnea severity scores and daytime sleepiness
Cardiovascular risk factors: Reduced triglycerides, improved LDL and HDL profiles, decreased inflammation markers
Mobility and quality of life: Patients reported significantly better physical function and quality of life scores at 72 weeks
Transparent Pricing

Zepbound® Pricing at Truventa Medical

We believe you should know exactly what you're getting into. No hidden fees, no surprises.

Consultation

Medical Consultation

Free

No credit card required to get started

A board-certified physician reviews your complete medical history, evaluates your eligibility for Zepbound®, and coordinates your prescription if you qualify. Insurance verification included at no cost.

  • Licensed board-certified physician review
  • Full eligibility assessment
  • Insurance verification included
  • Prior authorization support
  • HIPAA-secure and confidential
Start Free Consultation
Zepbound® Prescription

Zepbound® (Tirzepatide)

Insurance Pricing Varies

Savings programs available — as low as $25/mo for eligible patients

Zepbound® is covered by many commercial insurance plans. Our team handles prior authorization and helps you access all available savings programs, including the official Eli Lilly savings card for eligible patients.

  • Monthly auto-injector pen (all available doses)
  • All doses available: 2.5mg through 15mg
  • Ongoing prescription management
  • Monthly physician check-ins included
  • Dose adjustment support
Check My Options
The Zepbound Savings Card from Eli Lilly may reduce your monthly out-of-pocket cost to as little as $25/month for commercially insured patients who qualify. Our team will help you determine eligibility and navigate all available savings options — at no charge to you.
FAQ

Zepbound® — Frequently Asked Questions

Everything you need to know about getting Zepbound® prescribed online, how it works, and what to expect.

Zepbound® (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it activates two separate hormone receptors simultaneously — GIP and GLP-1. Wegovy® and Ozempic® (both semaglutide) only activate the GLP-1 receptor. This dual-action mechanism is why Zepbound® produces significantly greater weight loss than semaglutide-based medications. In the SURMOUNT-5 head-to-head trial, Zepbound® patients lost 47% more weight than Wegovy® patients over 72 weeks. Ozempic® is approved for type 2 diabetes management, while Wegovy® and Zepbound® are both specifically approved for chronic weight management in adults.
Zepbound® is covered by many commercial insurance plans, but coverage varies significantly depending on your insurer and specific plan. Eli Lilly offers the Zepbound Savings Card, which may reduce out-of-pocket costs to as little as $25 per month for commercially insured patients who qualify. Medicare and Medicaid coverage is more limited at this time. At Truventa Medical, our team provides free insurance verification and handles prior authorization paperwork on your behalf, so you can understand your true out-of-pocket cost before committing to treatment.
Most patients notice reduced appetite and early weight loss within the first 2–4 weeks of starting Zepbound®. The starter dose is 2.5mg per week, which focuses on building tolerance rather than maximum weight loss. Significant appetite suppression typically begins at the 5mg dose (weeks 5–8). The most substantial weight loss generally occurs between months 3–12 as the dose is gradually optimized. In clinical trials, participants lost an average of 5–10% of body weight within the first 3 months, with continued loss throughout the full 72-week study period. Your individual pace of loss will depend on your starting weight, dose, and lifestyle factors.
The most common side effects of Zepbound® are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach discomfort. These effects are most common during dose escalation and typically improve significantly within 2–4 weeks as your body adjusts. The gradual dose escalation schedule is specifically designed to minimize these effects. More serious but rare risks include pancreatitis, gallbladder disease, and injection site reactions. Zepbound® carries a boxed warning for thyroid C-cell tumors and should not be used by patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Your Truventa physician will review all contraindications during your consultation.
Yes — switching from Wegovy® (semaglutide) to Zepbound® (tirzepatide) is something many patients choose to do, especially when they want to maximize their weight loss results. Clinical trial data strongly supports Zepbound® as the more effective option in head-to-head comparison. The transition typically involves stopping semaglutide and starting Zepbound® at the 2.5mg starter dose, regardless of what dose of semaglutide you were taking. Your Truventa physician will guide the transition carefully and monitor you closely during the changeover to ensure comfort and safety throughout.
Zepbound® is available in six doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg — all administered as once-weekly subcutaneous injections using a single-use auto-injector pen. Treatment always starts at 2.5mg for the first four weeks, then escalates every four weeks as tolerated. The maximum approved dose is 15mg per week. Many patients achieve excellent results at 10mg and do not need to increase further. Your Truventa physician will determine the right maintenance dose based on your weight loss response, tolerance, and health goals.
While Zepbound® significantly reduces appetite on its own, combining it with healthier eating habits will meaningfully improve your outcomes. Clinical trials were conducted alongside lifestyle modifications, including reduced-calorie diets and increased physical activity. Most physicians recommend focusing on adequate protein intake — around 0.7 to 1 gram per pound of goal body weight — to preserve lean muscle mass during weight loss. You do not need a strict or complicated diet plan to succeed on Zepbound®. The medication naturally reduces cravings and portion sizes, making healthier food choices far easier than trying to diet alone. Your Truventa care team provides personalized nutrition guidance as part of your treatment protocol.

Start Your Zepbound® Journey Today

The most effective weight loss medication available is now accessible online. Licensed physicians in all 50 states, free consultation, and transparent pricing. Your transformation starts with one simple step.

Start My Free Consultation

No commitment·Cancel anytime·HIPAA-secure